ASSIST

GE HealthCare to Feature Latest Technologies in Interventional Radiology Focused on Precision Care at SIR 2024

Retrieved on: 
Friday, March 22, 2024
Software, Radiology, Surgery, General Health, Health, Artificial Intelligence, Medical Devices, Technology, PAE, Interventional radiology, Automation, 2D, ASSIST, Vascular disease, Drainage, Prostatic artery embolization, Allia, OEC, Patient, Artificial intelligence, Society of Interventional Radiology, 3D, Prostate, AI, Quality of life, Artery, Woman, Workflow, GE HealthCare, 3D CT, Embo, E10, Injection, Therapy, BPH, SIR, Medical imaging

GE HealthCare (Nasdaq: GEHC) will showcase its latest technologies in image guiding solutions, surgery, ultrasound and CT-navigation at the upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting taking place March 23-28 in Salt Lake City, UT.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC) will showcase its latest technologies in image guiding solutions, surgery, ultrasound and CT-navigation at the upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting taking place March 23-28 in Salt Lake City, UT.
  • The multi-modality showcase will feature innovations focused on precision care delivery for a wide range of vascular diseases and health conditions.
  • As GE HealthCare continues to advance the Allia IGS platform and interventional innovation, Embo ASSIST AI is the latest addition to the company's ASSIST imaging software.
  • “Interventional CT: CT guidance assisted by electromagnetic navigation for percutaneous interventions” with Dr. Francois Cornelis10 on Monday, March 25 from 2:30 - 3:00pm.

InventHelp Inventor Develops Assistive Device for Pets Climbing into Vehicles (DAL-402)

Retrieved on: 
Friday, February 2, 2024
ASSIST, Sale, Dog, Suite, PET

My design would be easy to set up and transport.”

Key Points: 
  • My design would be easy to set up and transport.”
    The patent-pending invention provides a device to help dogs into and out of vehicles.
  • In doing so, it offers an alternative to lifting the dog.
  • As a result, it reduces the impact on a dog’s joints and it increases comfort and convenience.
  • 22-DAL-402, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.

Rita and Alex Hillman Foundation Awards $1.2 Million to Nursing-Driven Innovations that Improve Care for Youth

Retrieved on: 
Tuesday, October 17, 2023
Parent, Health, Partnership, University, ASSIST, Homelessness, Mental, Mental health, Nursing, CPP, HIC, Parenting, Refugee, Health Resources and Services Administration, Child, Rita, Reinsurance, BIPOC, Johns Hopkins University, Pharmaceutical industry

NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- The Rita and Alex Hillman Foundation today announced two new grants from the Hillman Innovations in Care (HIC) program.

Key Points: 
  • NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- The Rita and Alex Hillman Foundation today announced two new grants from the Hillman Innovations in Care (HIC) program.
  • The awards, totalling $1.2 million, are to nurse researchers at the University of Pennsylvania and Johns Hopkins University.
  • These populations include Black, Indigenous, and People of Color (BIPOC), the economically disadvantaged, LGBTQ+ people, people experiencing homelessness, rural populations, refugees, and others.
  • “We believe that nursing innovation is a powerful force for change,” said Ahrin Mishan, Executive Director of The Rita and Alex Hillman Foundation.

Alliance One Recognized for Women Empowerment Efforts

Retrieved on: 
Wednesday, October 4, 2023
Poverty, Education, ASSIST, Farmer, Tobacco, Woman, Mentorship, Risk, Pyxus International, AOII, Empowerment, Female, Tourism

MORRISVILLE, N.C., Oct. 4, 2023 /PRNewswire/ -- Alliance One International, LLC ("Alliance One") is pleased to announce that its subsidiary, Alliance One Industries India Pvt.

Key Points: 
  • MORRISVILLE, N.C., Oct. 4, 2023 /PRNewswire/ -- Alliance One International, LLC ("Alliance One") is pleased to announce that its subsidiary, Alliance One Industries India Pvt.
  • "It is an honor to be recognized for our efforts to empower women in an area of the world where, historically, the education, career opportunities and overall well-being of women have not been prioritized by society," said David Hird, Alliance One's Regional Director of Asia.
  • Participants also receive mentoring from other women who have successfully improved their economic viability from their own participation in the Women Empowerment Project.
  • Since its inception, 186 women have benefitted from the Women Empowerment Project, reporting on average an approximate 10% increase in their respective monthly household incomes.

InventHelp Inventor Develops New Squat Assist Device (MHO-288)

Retrieved on: 
Thursday, August 10, 2023
Exercise, ASSIST, Leg, Multimedia, Falls, Risk, Injury, Sale

PITTSBURGH, Aug. 10, 2023 /PRNewswire/ -- "I wanted to create an exercise accessory to aid in simple but safe squat and push-up exercises for all users from beginners to seniors," said an inventor, from Troy, Mo., "so I invented the SQUAT ASSIST DEVICE.

Key Points: 
  • PITTSBURGH, Aug. 10, 2023 /PRNewswire/ -- "I wanted to create an exercise accessory to aid in simple but safe squat and push-up exercises for all users from beginners to seniors," said an inventor, from Troy, Mo., "so I invented the SQUAT ASSIST DEVICE.
  • The patent-pending invention provides an exercise/fitness device for performing safe and effective squat exercises.
  • The original design was submitted to the National sales office of InventHelp.
  • 21-MHO-288, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

Retrieved on: 
Monday, June 12, 2023
1991 World Sportscar Championship, PD, IV, ASSIST, Cohort, Pharmacokinetics, Research, Part, Immunoglobulin A, Biomarker, EDT, ERA, Congress, Proteinuria, Acquisition, HIV disease progression rates, Patient, CEST, Kidney, IgA nephropathy, Immunoglobulin G, Therapy, Chronic kidney disease-mineral and bone disorder, Kidney disease, Safety, Novartis, Pharmaceutical industry, Vaccine, Health insurance, Chinook

Blocking APRIL is a potentially disease-modifying approach to treating IgAN by reducing circulating levels of galactose-deficient IgA1 (Gd-IgA1).

Key Points: 
  • Blocking APRIL is a potentially disease-modifying approach to treating IgAN by reducing circulating levels of galactose-deficient IgA1 (Gd-IgA1).
  • Key highlights from the presentation include the following:
    Patients in Cohort 1 initially received a 450mg intravenous (IV) dose of zigakibart every two weeks.
  • Cohort 1 enrolled 10 patients, of which two patients withdrew from the study for reasons unrelated to study drug, and eight patients continued receiving treatment.
  • Of all 40 patients enrolled in both Cohorts 1 and 2:
    There were no anti-drug antibodies observed in any patients.

InventHelp Inventor Develops Improved Address Plaque to Increase Visibility (LUW-113)

Retrieved on: 
Wednesday, May 31, 2023
ASSIST, Confusion, Plaque, Address, Multimedia, Sale, Television

The patent-pending invention provides an improved address plaque for households or businesses.

Key Points: 
  • The patent-pending invention provides an improved address plaque for households or businesses.
  • In doing so, it increases the visibility of the address.
  • As a result, it reduces difficulties and confusion when looking for the address.
  • It also eliminates the need for a power source to illuminate the plaque.

Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Tuesday, May 9, 2023
ERA, Congress, Investigational New Drug, Patient, Focal segmental glomerulosclerosis, Merck, Diabetic nephropathy, Alport syndrome, Proteinuria, Primary hyperoxaluria, MAD, FDA, IND, Safety, Lundbeck Seattle Biopharmaceuticals, LDHA, European Renal Association, ASSIST, Cohort, FSGS, ETA, Kidney, IgA nephropathy, Juno Therapeutics, Research, Therapy, Type D, Juno, SC, Nephrology, Clinical trial, SAD, Part, SGLT2, Immunoglobulin A, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Chronic kidney disease, Food, Pharmaceutical industry, Atrasentan, Chinook

SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the first quarter ended March 31, 2023 and provided corporate updates.

Key Points: 
  • SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the first quarter ended March 31, 2023 and provided corporate updates.
  • “During the first quarter of 2023, we continued to advance our pipeline of clinical and preclinical programs for rare, severe chronic kidney diseases.
  • Chinook plans to present data from one or more additional cohorts of the AFFINITY trial in the second half of 2023.
  • Revenue – Revenue for the quarter ended March 31, 2023 was $1.8 million compared to $2.7 million for the same period in 2022.

Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress

Retrieved on: 
Friday, May 5, 2023
Abstract, FRCP, University, ASSIST, Research, Doctor of Philosophy, EDT, Atrasentan, Congress, HIV disease progression rates, Patient, Kidney, IgA nephropathy, Webcast, Therapy, Chronic kidney disease, Pharmaceutical industry, Chinook

The five accepted abstracts will be delivered as three focused orals (digital poster with 3-minute presentation), one free communication (10-minute live oral presentation) and one moderated oral presentation (6-slide presentation).

Key Points: 
  • The five accepted abstracts will be delivered as three focused orals (digital poster with 3-minute presentation), one free communication (10-minute live oral presentation) and one moderated oral presentation (6-slide presentation).
  • Chinook will host a live conference call and webcast on Friday, June 16, 2023 at 8:15 am EDT to review and discuss the abstracts and provide corporate updates.
  • Members of the Chinook executive team will be joined by Jonathan Barratt, PhD, FRCP, Mayer Professor of Renal Medicine at University of Leicester in Leicester, UK for a discussion on Chinook’s programs.
  • University of Leicester & Leicester General Hospital, Leicester, UK

Civix and Zwipe Initiate Proof-of-Concept with Safe Skies at Richmond International Airport

Retrieved on: 
Monday, May 1, 2023
Federal Aviation Administration, Sky, ASC, Partnership, Richmond International Airport, ASSIST, Safe, Richmond Airport, COVID-19, Airport, Government, FAA, NFC, Risk, POC, Environment, TSA, RIC, Transport, Airline

"We're pleased to have Safe Skies involved in third-party testing of the ASC Access biometric card solution in a real-world airport environment at the Richmond Airport," said Tim Walsh, President of Civix Airports.

Key Points: 
  • "We're pleased to have Safe Skies involved in third-party testing of the ASC Access biometric card solution in a real-world airport environment at the Richmond Airport," said Tim Walsh, President of Civix Airports.
  • "We are excited to be in partnership with Safe Skies and Civix and we are grateful to them for making this opportunity possible."
  • National Safe Skies Alliance, Inc. (Safe Skies) is a non-profit organization that works with airports, government, and related industries to maintain a safe and effective aviation security system.
  • "We're pleased to have Safe Skies involved in third-party testing of the ASC Access biometric card solution in a real-world airport environment at the Richmond Airport," said Tim Walsh, President of Civix Airports.